Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia

Objective: CSE-1034 is a novel antibiotic adjuvant entity (AAE) with proven activity against broad range of multi-drug resistant (MDR) pathogens causing various bacterial infections. This phase 3 clinical trial was designed to evaluate the efficacy and safety of CSE-1034 therapy for the treatment of...

Full description

Bibliographic Details
Main Authors: Manu Chaudhary, Shiekh G. Ayub, Mohd A. Mir
Format: Article
Language:English
Published: Elsevier 2018-09-01
Series:Journal of Infection and Public Health
Online Access:http://www.sciencedirect.com/science/article/pii/S187603411830042X
id doaj-bf9553db800f4ffa924d813cfc5eb2f4
record_format Article
spelling doaj-bf9553db800f4ffa924d813cfc5eb2f42020-11-25T02:26:50ZengElsevierJournal of Infection and Public Health1876-03412018-09-01115691697Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumoniaManu Chaudhary0Shiekh G. Ayub1Mohd A. Mir2Department of Clinical Research, Venus Remedies, Panchkula, 134114, IndiaDepartment of Clinical Research, Venus Remedies, Panchkula, 134114, IndiaCorresponding author at: Venus Medicine Research Center, Venus Remedies Ltd., India.; Department of Clinical Research, Venus Remedies, Panchkula, 134114, IndiaObjective: CSE-1034 is a novel antibiotic adjuvant entity (AAE) with proven activity against broad range of multi-drug resistant (MDR) pathogens causing various bacterial infections. This phase 3 clinical trial was designed to evaluate the efficacy and safety of CSE-1034 therapy for the treatment of community-acquired pneumonia (CAP) patients of Pneumonia Outcomes Research Team (PORT) risk III–IV. Methods: In this multi-centric, controlled, open-labeled phase 3 trial, adult patients with PORT risk III–IV CAP were randomized to receive either intravenous CSE-1034 (3 g every 12 h) or Ceftriaxone (2 g every 12 h) for 3–10 days. The primary endpoint was clinical response in clinically-evaluable (CE) population and microbiological eradication in microbiologically-evaluable (ME) population at test of cure (TOC) visits. Secondary endpoints included verification of the primary endpoints across all other visits, treatment duration and safety of patients. Results: 156 patients were screened at 5 study centers of which 93 subjects were enrolled in the study and randomized in CSE-1034 and Ceftriaxone treatment arms. In CE population (n = 90), the clinical cure rates at TOC visit were 96% and 64% in CSE-1034 (n = 46) and Ceftriaxone (n = 44) treatment arms respectively (treatment difference: 32.0%; 95% CI, 15.8%–47.1%). The bacterial eradication in ME population of two treatment arms were 94% (n = 36) and 56% (n = 27) at TOC visit (treatment difference: 38.9%; 95% CI, 17.8%–57.6%). Overall, the total number of adverse events (AEs) reported in both groups were 21 (22.5%). The AEs rates reported in two treatment arms were 15.2% in CSE-1034 and 29.8% in Ceftriaxone group. Conclusion: Overall assessment of clinical cure rate, microbiological eradication rate and safety assessment in this study has shown that CSE-1034 is an effective and safe option for the treatment of CAP patients of PORT risk III–IV. Moreover, the superiority of CSE-1034 over Ceftriaxone is also proven. Keywords: CSE-1034, CAP, Ceftriaxone, Anti-microbial resistancehttp://www.sciencedirect.com/science/article/pii/S187603411830042X
collection DOAJ
language English
format Article
sources DOAJ
author Manu Chaudhary
Shiekh G. Ayub
Mohd A. Mir
spellingShingle Manu Chaudhary
Shiekh G. Ayub
Mohd A. Mir
Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
Journal of Infection and Public Health
author_facet Manu Chaudhary
Shiekh G. Ayub
Mohd A. Mir
author_sort Manu Chaudhary
title Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
title_short Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
title_full Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
title_fullStr Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
title_full_unstemmed Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
title_sort comparative efficacy and safety analysis of cse-1034: an open labeled phase iii study in community acquired pneumonia
publisher Elsevier
series Journal of Infection and Public Health
issn 1876-0341
publishDate 2018-09-01
description Objective: CSE-1034 is a novel antibiotic adjuvant entity (AAE) with proven activity against broad range of multi-drug resistant (MDR) pathogens causing various bacterial infections. This phase 3 clinical trial was designed to evaluate the efficacy and safety of CSE-1034 therapy for the treatment of community-acquired pneumonia (CAP) patients of Pneumonia Outcomes Research Team (PORT) risk III–IV. Methods: In this multi-centric, controlled, open-labeled phase 3 trial, adult patients with PORT risk III–IV CAP were randomized to receive either intravenous CSE-1034 (3 g every 12 h) or Ceftriaxone (2 g every 12 h) for 3–10 days. The primary endpoint was clinical response in clinically-evaluable (CE) population and microbiological eradication in microbiologically-evaluable (ME) population at test of cure (TOC) visits. Secondary endpoints included verification of the primary endpoints across all other visits, treatment duration and safety of patients. Results: 156 patients were screened at 5 study centers of which 93 subjects were enrolled in the study and randomized in CSE-1034 and Ceftriaxone treatment arms. In CE population (n = 90), the clinical cure rates at TOC visit were 96% and 64% in CSE-1034 (n = 46) and Ceftriaxone (n = 44) treatment arms respectively (treatment difference: 32.0%; 95% CI, 15.8%–47.1%). The bacterial eradication in ME population of two treatment arms were 94% (n = 36) and 56% (n = 27) at TOC visit (treatment difference: 38.9%; 95% CI, 17.8%–57.6%). Overall, the total number of adverse events (AEs) reported in both groups were 21 (22.5%). The AEs rates reported in two treatment arms were 15.2% in CSE-1034 and 29.8% in Ceftriaxone group. Conclusion: Overall assessment of clinical cure rate, microbiological eradication rate and safety assessment in this study has shown that CSE-1034 is an effective and safe option for the treatment of CAP patients of PORT risk III–IV. Moreover, the superiority of CSE-1034 over Ceftriaxone is also proven. Keywords: CSE-1034, CAP, Ceftriaxone, Anti-microbial resistance
url http://www.sciencedirect.com/science/article/pii/S187603411830042X
work_keys_str_mv AT manuchaudhary comparativeefficacyandsafetyanalysisofcse1034anopenlabeledphaseiiistudyincommunityacquiredpneumonia
AT shiekhgayub comparativeefficacyandsafetyanalysisofcse1034anopenlabeledphaseiiistudyincommunityacquiredpneumonia
AT mohdamir comparativeefficacyandsafetyanalysisofcse1034anopenlabeledphaseiiistudyincommunityacquiredpneumonia
_version_ 1724845409126318080